<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
	<!-- headlinks removed -->
	<link rel="shortcut icon" href="../../../../misc/favicon.ico"/>
    <title>Mechanism of action of aspirin - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../../skins/offline/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../../skins/offline/md5.js"></script>
    <script type="text/javascript" src="../../../../skins/offline/utf8.js"></script>
    <script type="text/javascript" src="../../../../skins/offline/lookup.js"></script>
    <script type="text/javascript" src="../../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../../raw/MediaWiki%7ECommon.css";
@import "../../../../raw/MediaWiki%7EMonobook.css";
@import "../../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Mechanism of action of aspirin</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    	    <!-- start content -->
	    <div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="../../../../articles/a/s/p/Image%7EAspirin-3D-balls.png_96ef.html" class="image" title="3D model of chemical structure of aspirin"><img alt="3D model of chemical structure of aspirin" src="../../../../images/shared/thumb/6/6a/Aspirin-3D-balls.png/180px-Aspirin-3D-balls.png" width="180" height="166" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="../../../../articles/a/s/p/Image%7EAspirin-3D-balls.png_96ef.html" class="internal" title="Enlarge"><img src="../../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
3D model of chemical structure of aspirin</div>
</div>
</div>
<p><a href="../../../../articles/a/s/p/Aspirin.html" title="Aspirin">Aspirin</a> causes several different effects in the body, mainly the <a href="../../../../articles/a/n/t/Anti-inflammatory.html" title="Anti-inflammatory">reduction of inflammation</a>, <a href="../../../../articles/a/n/a/Analgesia.html" class="mw-redirect" title="Analgesia">analgesia</a> (relief of pain), <a href="../../../../articles/b/l/e/Bleeding.html" title="Bleeding">bleeding</a> and the prevention of <a href="../../../../articles/c/l/o/Clotting.html" class="mw-redirect" title="Clotting">clotting</a>, and the <a href="../../../../articles/a/n/t/Antipyretic.html" title="Antipyretic">reduction of fever</a>. Much of this is believed to be due to decreased production of <a href="../../../../articles/p/r/o/Prostaglandins.html" class="mw-redirect" title="Prostaglandins">prostaglandins</a> and <a href="../../../../articles/t/h/r/Thromboxanes.html" class="mw-redirect" title="Thromboxanes">thromboxanes</a>. Aspirin's ability to suppress the production of prostaglandins and thromboxanes is due to its irreversible inactivation of the <a href="../../../../articles/c/y/c/Cyclooxygenase.html" title="Cyclooxygenase">cyclooxygenase</a> (COX) enzyme. Cyclooxygenase is required for prostaglandin and thromboxane synthesis. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a <a href="../../../../articles/s/e/r/Serine.html" title="Serine">serine</a> residue in the active site of the COX enzyme. This makes aspirin different from other NSAIDs (such as <a href="../../../../articles/d/i/c/Diclofenac.html" title="Diclofenac">diclofenac</a> and <a href="../../../../articles/i/b/u/Ibuprofen.html" title="Ibuprofen">ibuprofen</a>), which are reversible inhibitors. However, other effects of aspirin, such as uncoupling <a href="../../../../articles/o/x/i/Oxidative_phosphorylation.html" title="Oxidative phosphorylation">oxidative phosphorylation</a> in <a href="../../../../articles/m/i/t/Mitochondria.html" class="mw-redirect" title="Mitochondria">mitochondria</a>, and the modulation of signaling through <a href="../../../../articles/n/f/-/NF-%CE%BAB_3b0d.html" title="NF-κB">NF-κB</a>, are also being investigated.</p>
<p><br /></p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#History_of_Discovery"><span class="tocnumber">1</span> <span class="toctext">History of Discovery</span></a></li>
<li class="toclevel-1"><a href="#Effects_on_cyclooxygenase"><span class="tocnumber">2</span> <span class="toctext">Effects on cyclooxygenase</span></a></li>
<li class="toclevel-1"><a href="#Effects_on_prostaglandins_and_thromboxanes"><span class="tocnumber">3</span> <span class="toctext">Effects on prostaglandins and thromboxanes</span></a></li>
<li class="toclevel-1"><a href="#Other_methods_of_action"><span class="tocnumber">4</span> <span class="toctext">Other methods of action</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">5</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">6</span> <span class="toctext">References</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="History_of_Discovery" id="History_of_Discovery"></a></p>
<h2><span class="editsection">[<a href="../../../../articles/m/e/c/Mechanism_of_action_of_aspirin.html" title="Edit section: History of Discovery">edit</a>]</span> <span class="mw-headline">History of Discovery</span></h2>
<dl>
<dd><span class="boilerplate seealso"><i>See also: <a href="../../../../articles/h/i/s/History_of_aspirin.html" title="History of aspirin">History of aspirin</a></i></span></dd>
</dl>
<p>The mechanism of aspirin's analgesic, anti-inflammatory and antipyretic properties was unknown through the drug's heyday in the early- to mid-twentieth century; Heinrich Dreser's explanation, widely accepted since the drug was first brought to market, was that aspirin relieved pain by acting on the <a href="../../../../articles/c/e/n/Central_nervous_system.html" title="Central nervous system">central nervous system</a>. In 1958 Harry Collier, a biochemist in the London laboratory of pharmaceutical company <a href="../../../../articles/p/a/r/Parke_Davis_7e73.html" class="mw-redirect" title="Parke Davis">Parke Davis</a>, began investigating the relationship between <a href="../../../../articles/k/i/n/Kinin-kallikrein_system.html" title="Kinin-kallikrein system">kinins</a> and the effects of aspirin. In tests on <a href="../../../../articles/g/u/i/Guinea_pig.html" title="Guinea pig">guinea pigs</a>, Collier found that aspirin, if given beforehand, inhibited the <a href="../../../../articles/b/r/o/Bronchoconstriction.html" title="Bronchoconstriction">bronchoconstriction</a> effects of <a href="../../../../articles/b/r/a/Bradykinin.html" title="Bradykinin">bradykinin</a>. He found that cutting the guinea pigs' <a href="../../../../articles/v/a/g/Vagus_nerve.html" title="Vagus nerve">vagus nerve</a> did not affect the action of bradykinin <i>or</i> the inhibitory effect of aspirin—evidence that aspirin worked locally to combat pain and inflammation, rather than on the central nervous system. In 1963, Collier began working with <a href="../../../../articles/u/n/i/University_of_London_fd08.html" title="University of London">University of London</a> pharmacology graduate student Priscilla Piper to determine the precise mechanism of aspirin's effects. However, it was difficult to pin down the precise biochemical goings-on in live research animals, and <i><a href="../../../../articles/i/n/_/In_vitro.html" title="In vitro">in vitro</a></i> tests on removed animal tissues did not behave like <i><a href="../../../../articles/i/n/_/In_vivo.html" title="In vivo">in vivo</a></i> tests. <sup id="cite_ref-0" class="reference"><a href="#cite_note-0" title="">[1]</a></sup></p>
<p>After five years of collaboration, Collier arranged for Piper to work with pharmacologist <a href="../../../../articles/j/o/h/John_Vane_5c01.html" class="mw-redirect" title="John Vane">John Vane</a> at the <a href="../../../../articles/r/o/y/Royal_College_of_Surgeons_f2c0.html" title="Royal College of Surgeons">Royal College of Surgeons</a>, in order to learn Vane's new <a href="../../../../articles/b/i/o/Bioassay.html" title="Bioassay">bioassay</a> methods, which seemed like a possible solution to the <i>in vitro</i> testing failures. Vane and Piper tested the <a href="../../../../articles/b/i/o/Biochemical_cascade.html" title="Biochemical cascade">biochemical cascade</a> associated with <a href="../../../../articles/a/n/a/Anaphylactic_shock.html" class="mw-redirect" title="Anaphylactic shock">anaphylactic shock</a> (in extracts from guinea pig lungs, applied to tissue from <a href="../../../../articles/r/a/b/Rabbit.html" title="Rabbit">rabbit</a> <a href="../../../../articles/a/o/r/Aorta.html" title="Aorta">aortas</a>). They found that aspirin inhibited the release of an unidentified chemical generated by guinea pig lungs, a chemical that caused rabbit tissue to contract. By 1971, Vane identified the chemical (which they called "rabbit-aorta contracting substance," or RCS) as a <a href="../../../../articles/p/r/o/Prostaglandin.html" title="Prostaglandin">prostaglandin</a>. In a <a href="../../../../articles/j/u/n/June_23.html" title="June 23">June 23</a>, <a href="../../../../articles/1/9/7/1971.html" title="1971">1971</a> paper in the journal <i><a href="../../../../articles/n/a/t/Nature_%28journal%29.html" title="Nature (journal)">Nature</a></i>, Vane and Piper suggested that aspirin and similar drugs (the <a href="../../../../articles/n/o/n/Non-steroidal_anti-inflammatory_drug.html" title="Non-steroidal anti-inflammatory drug">non-steroidal anti-inflammatory drugs</a> or NSAIDs) worked by blocking the production of prostaglandins. For this discovery, Vane was awarded both a <a href="../../../../articles/n/o/b/Nobel_Prize_c061.html" title="Nobel Prize">Nobel Prize</a> in <a href="../../../../articles/n/o/b/Nobel_Prize_in_Physiology_or_Medicine_b5e4.html" title="Nobel Prize in Physiology or Medicine">Physiology or Medicine</a> in 1982 and a <a href="../../../../articles/k/n/i/Knighthood.html" class="mw-redirect" title="Knighthood">knighthood</a>. Later research showed that NSAIDs such as aspirin worked by inhibiting <a href="../../../../articles/c/y/c/Cyclooxygenase.html" title="Cyclooxygenase">cyclooxygenase</a>, the enzyme responsible for converting <a href="../../../../articles/a/r/a/Arachidonic_acid.html" title="Arachidonic acid">arachidonic acid</a> into a prostaglandin.<sup id="cite_ref-1" class="reference"><a href="#cite_note-1" title="">[2]</a></sup></p>
<p><a name="Effects_on_cyclooxygenase" id="Effects_on_cyclooxygenase"></a></p>
<h2><span class="editsection">[<a href="../../../../articles/m/e/c/Mechanism_of_action_of_aspirin.html" title="Edit section: Effects on cyclooxygenase">edit</a>]</span> <span class="mw-headline">Effects on cyclooxygenase</span></h2>
<dl>
<dd><span class="boilerplate seealso"><i>See also: <a href="../../../../articles/c/y/c/Cyclooxygenase.html" title="Cyclooxygenase">cyclooxygenase</a></i></span></dd>
</dl>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="../../../../articles/c/o/x/Image%7ECOX-2_inhibited_by_Aspirin.png_774f.html" class="image" title="Structure of COX-2 inactivated by Aspirin. In the active site of each of the two monomers, Serine 530 has been acetylated. Also visible is the salicylic acid which has transferred the acyl group, and the heme cofactor."><img alt="Structure of COX-2 inactivated by Aspirin. In the active site of each of the two monomers, Serine 530 has been acetylated. Also visible is the salicylic acid which has transferred the acyl group, and the heme cofactor." src="../../../../images/shared/thumb/4/42/COX-2_inhibited_by_Aspirin.png/180px-COX-2_inhibited_by_Aspirin.png" width="180" height="113" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="../../../../articles/c/o/x/Image%7ECOX-2_inhibited_by_Aspirin.png_774f.html" class="internal" title="Enlarge"><img src="../../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Structure of COX-2 inactivated by Aspirin. In the active site of each of the two monomers, Serine 530 has been acetylated. Also visible is the salicylic acid which has transferred the acyl group, and the heme cofactor.</div>
</div>
</div>
<p>There are at least two (and possibly three<sup id="cite_ref-cox3article_2-0" class="reference"><a href="#cite_note-cox3article-2" title="">[3]</a></sup>) different types of cyclooxygenase: COX-1 and COX-2. Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. Normally COX produces prostaglandins, most of which are pro-inflammatory, and thromboxanes, which promote clotting. Aspirin-modified COX-2 produces lipoxins, most of which are anti-inflammatory. Newer NSAID drugs called <a href="../../../../articles/c/o/x/COX-2_selective_inhibitor_6b7f.html" class="mw-redirect" title="COX-2 selective inhibitor">COX-2 selective inhibitors</a> have been developed that inhibit only COX-2, with the hope for reduction of gastrointestinal side-effects.<sup id="cite_ref-cox3article_2-1" class="reference"><a href="#cite_note-cox3article-2" title="">[3]</a></sup></p>
<p>However, several of the new <a href="../../../../articles/c/o/x/COX-2_selective_inhibitor_6b7f.html" class="mw-redirect" title="COX-2 selective inhibitor">COX-2 selective inhibitors</a> have been recently withdrawn (see <a href="../../../../articles/v/i/o/Vioxx.html" class="mw-redirect" title="Vioxx">Vioxx</a>), after evidence emerged that COX-2 inhibitors increase the risk of heart attack. It is proposed that endothelial cells lining the microvasculature in the body express COX-2, and, by selectively inhibiting COX-2, prostaglandins (specifically PGI2; prostacyclin) are downregulated with respect to thromboxane levels, as COX-1 in platelets is unaffected. Thus, the protective anti-coagulative effect of PGI2 is decreased, increasing the risk of thrombus and associated heart attacks and other circulatory problems. Since platelets have no DNA, they are unable to synthesize new COX once aspirin has irreversibly inhibited the enzyme, an important difference with reversible inhibitors.</p>
<p><a name="Effects_on_prostaglandins_and_thromboxanes" id="Effects_on_prostaglandins_and_thromboxanes"></a></p>
<h2><span class="editsection">[<a href="../../../../articles/m/e/c/Mechanism_of_action_of_aspirin.html" title="Edit section: Effects on prostaglandins and thromboxanes">edit</a>]</span> <span class="mw-headline">Effects on prostaglandins and thromboxanes</span></h2>
<dl>
<dd><span class="boilerplate seealso"><i>See also: <a href="../../../../articles/p/r/o/Prostaglandins.html" class="mw-redirect" title="Prostaglandins">prostaglandins</a>&#160;and <a href="../../../../articles/t/h/r/Thromboxanes.html" class="mw-redirect" title="Thromboxanes">thromboxanes</a></i></span></dd>
</dl>
<p>Aspirin's ability to suppress the production of prostaglandins and thromboxanes is due to its irreversible inactivation of the <a href="../../../../articles/c/y/c/Cyclooxygenase.html" title="Cyclooxygenase">cyclooxygenase</a> (COX) enzyme. Cyclooxygenase is required for prostaglandin and thromboxane synthesis. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a <a href="../../../../articles/s/e/r/Serine.html" title="Serine">serine</a> residue in the active site of the COX enzyme. This makes aspirin different from other NSAIDs (such as <a href="../../../../articles/d/i/c/Diclofenac.html" title="Diclofenac">diclofenac</a> and <a href="../../../../articles/i/b/u/Ibuprofen.html" title="Ibuprofen">ibuprofen</a>), which are reversible inhibitors.</p>
<p>Low-dose, long-term aspirin use irreversibly blocks the formation of <a href="../../../../articles/t/h/r/Thromboxane_A2_7aef.html" title="Thromboxane A2">thromboxane A<sub>2</sub></a> in <a href="../../../../articles/p/l/a/Platelet.html" title="Platelet">platelets</a>, producing an inhibitory effect on <a href="../../../../articles/p/l/a/Platelet.html" title="Platelet">platelet aggregation</a>. This anticoagulant property makes aspirin useful for reducing the incidence of heart attacks.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3" title="">[4]</a></sup> 40&#160;mg of aspirin a day is able to inhibit a large proportion of maximum thromboxane A<sub>2</sub> release provoked acutely, with the prostaglandin I2 synthesis being little affected; however, higher doses of aspirin are required to attain further inhibition.<sup id="cite_ref-4" class="reference"><a href="#cite_note-4" title="">[5]</a></sup></p>
<p>Prostaglandins are local <a href="../../../../articles/h/o/r/Hormone.html" title="Hormone">hormones</a> (paracrine) produced in the body and have diverse effects in the body, including but not limited to transmission of pain information to the brain, modulation of the <a href="../../../../articles/h/y/p/Hypothalamus.html" title="Hypothalamus">hypothalamic</a> thermostat, and inflammation. Thromboxanes are responsible for the aggregation of <a href="../../../../articles/p/l/a/Platelet.html" title="Platelet">platelets</a> that form <a href="../../../../articles/c/l/o/Clot.html" class="mw-redirect" title="Clot">blood clots</a>. Heart attacks are primarily caused by blood clots, and their reduction with the introduction of small amounts of aspirin has been seen to be an effective medical intervention. The side-effect of this is that the ability of the blood in general to clot is reduced, and excessive bleeding may result from the use of aspirin.</p>
<p><a name="Other_methods_of_action" id="Other_methods_of_action"></a></p>
<h2><span class="editsection">[<a href="../../../../articles/m/e/c/Mechanism_of_action_of_aspirin.html" title="Edit section: Other methods of action">edit</a>]</span> <span class="mw-headline">Other methods of action</span></h2>
<p>Aspirin has been shown to have at least three additional modes of action. It uncouples <a href="../../../../articles/o/x/i/Oxidative_phosphorylation.html" title="Oxidative phosphorylation">oxidative phosphorylation</a> in cartilaginous (and hepatic) mitochondria, by diffusing from the inner membrane space as a proton carrier back into the mitochondrial matrix, where it ionizes once again to release protons.<sup id="cite_ref-SomasundaramS_5-0" class="reference"><a href="#cite_note-SomasundaramS-5" title="">[6]</a></sup> In short, aspirin buffers and transports the protons. When high doses of aspirin are given, aspirin may actually cause fever due to the heat released from the electron transport chain, as opposed to the antipyretic action of aspirin seen with lower doses. Additionally, aspirin induces the formation of NO-radicals in the body, which have been shown in mice to have an independent mechanism of reducing inflammation. This reduced leukocyte adhesion, which is an important step in immune response to infection; however, there is currently insufficient evidence to show that aspirin helps to fight infection.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6" title="">[7]</a></sup> More recent data also suggests that salicylic acid and its derivatives modulate signaling through <a href="../../../../articles/n/f/-/NF-%CE%BAB_3b0d.html" title="NF-κB">NF-κB</a>.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7" title="">[8]</a></sup> NF-κB is a <a href="../../../../articles/t/r/a/Transcription_factor.html" title="Transcription factor">transcription factor</a> complex that plays a central role in many biological processes, including inflammation.</p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../../articles/m/e/c/Mechanism_of_action_of_aspirin.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<p><a href="../../../../articles/a/s/p/Aspirin.html" title="Aspirin">Aspirin</a><br />
<a href="../../../../articles/h/i/s/History_of_aspirin.html" title="History of aspirin">History of aspirin</a></p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../../articles/m/e/c/Mechanism_of_action_of_aspirin.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small">
<ol class="references">
<li id="cite_note-0"><b><a href="#cite_ref-0" title="">^</a></b> Jeffreys, <i>Aspirin</i>, pp. 223-226</li>
<li id="cite_note-1"><b><a href="#cite_ref-1" title="">^</a></b> Jeffreys, <i>Aspirin</i>, pp. 226-231</li>
<li id="cite_note-cox3article-2">^ <a href="#cite_ref-cox3article_2-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-cox3article_2-1" title=""><sup><i><b>b</b></i></sup></a> <a href="http://www.pnas.org/cgi/content/extract/99/21/13371" class="external text" title="http://www.pnas.org/cgi/content/extract/99/21/13371" rel="nofollow">Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? - Warner and Mitchell 99 (21): 13371 - Proceedings of the National Academy of Sciences</a></li>
<li id="cite_note-3"><b><a href="#cite_ref-3" title="">^</a></b> <a href="http://www.americanheart.org/presenter.jhtml?identifier=4456" class="external autonumber" title="http://www.americanheart.org/presenter.jhtml?identifier=4456" rel="nofollow">[1]</a> American Heart Association: <i>Aspirin in Heart Attack and Stroke Prevention</i> "The American Heart Association recommends aspirin use for patients who've had a myocardial infarction (heart attack), unstable angina, ischemic stroke (caused by blood clot) or transient ischemic attacks (TIAs or "little strokes"), if not contraindicated. This recommendation is based on sound evidence from clinical trials showing that aspirin helps prevent the recurrence of such events as heart attack, hospitalization for recurrent angina, second strokes, etc. (secondary prevention). Studies show aspirin also helps prevent these events from occurring in people at high risk (primary prevention)."</li>
<li id="cite_note-4"><b><a href="#cite_ref-4" title="">^</a></b> <cite style="font-style:normal">Tohgi, H; S Konno, K Tamura, B Kimura and K Kawano (1992). "Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin". <i>Stroke</i> <b>Vol 23</b>: 1400–1403. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1412574" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/1412574">PMID 1412574</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Effects+of+low-to-high+doses+of+aspirin+on+platelet+aggregability+and+metabolites+of+thromboxane+A2+and+prostacyclin&amp;rft.jtitle=Stroke&amp;rft.date=1992&amp;rft.volume=Vol+23&amp;rft.aulast=Tohgi&amp;rft.aufirst=H&amp;rft.pages=1400%E2%80%931403&amp;rft_id=info:pmid/1412574"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-SomasundaramS-5"><b><a href="#cite_ref-SomasundaramS_5-0" title="">^</a></b> <cite style="font-style:normal">Somasundaram, S. et al. (2000). "<a href="http://www.blackwell-synergy.com/doi/pdf/10.1046/j.1365-2036.2000.00723.x" class="external text" title="http://www.blackwell-synergy.com/doi/pdf/10.1046/j.1365-2036.2000.00723.x" rel="nofollow">Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat</a>". <i>Aliment Pharmacol Ther</i> <b>14</b>: 639-650.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Uncoupling+of+intestinal+mitochondrial+oxidative+phosphorylation+and+inhibition+of+cyclooxygenase+are+required+for+the+development+of+NSAID-enteropathy+in+the+rat&amp;rft.jtitle=Aliment+Pharmacol+Ther&amp;rft.date=2000&amp;rft.volume=14&amp;rft.aulast=Somasundaram%2C+S.+et+al.&amp;rft.pages=639-650&amp;rft_id=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fpdf%2F10.1046%2Fj.1365-2036.2000.00723.x"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-6"><b><a href="#cite_ref-6" title="">^</a></b> Mark J. Paul-Clark, Thong van Cao, Niloufar Moradi-Bidhendi, Dianne Cooper, and Derek W. Gilroy 15-epi-lipoxin A4–mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation J. Exp. Med. 200: 69-78; published online before print as 10.1084/jem.20040566</li>
<li id="cite_note-7"><b><a href="#cite_ref-7" title="">^</a></b> <cite style="font-style:normal">McCarty, MF; KI Block (2006). "Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy.". <i>Integr Cancer Ther.</i> <b>Vol 5</b> (3): 252–268. <a href="../../../../articles/d/i/g/Digital_object_identifier.html" title="Digital object identifier">doi</a>:<span class="plainlinks neverexpand"><a href="http://dx.doi.org/10.1177%2F1534735406291499" class="external text" title="http://dx.doi.org/10.1177%2F1534735406291499" rel="nofollow">10.1177/1534735406291499</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16880431" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16880431">PMID 16880431</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Preadministration+of+high-dose+salicylates%2C+suppressors+of+NF-kappaB+activation%2C+may+increase+the+chemosensitivity+of+many+cancers%3A+an+example+of+proapoptotic+signal+modulation+therapy.&amp;rft.jtitle=Integr+Cancer+Ther.&amp;rft.date=2006&amp;rft.volume=Vol+5&amp;rft.issue=3&amp;rft.aulast=McCarty&amp;rft.aufirst=MF&amp;rft.pages=252%E2%80%93268&amp;rft_id=info:pmid/16880431&amp;rft_id=info:doi/10.1177%2F1534735406291499"><span style="display: none;">&#160;</span></span></li>
</ol>
</div>


<!-- 
NewPP limit report
Preprocessor node count: 874/1000000
Post-expand include size: 7052/2048000 bytes
Template argument size: 3105/2048000 bytes
Expensive parser function count: 0/500
-->
<div class="printfooter">
</div>
	    <div id="catlinks"><div id='catlinks' class='catlinks'><div id="mw-normal-catlinks"><a href="../../../../articles/c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>:&#32;<span dir='ltr'><a href="../../../../articles/a/s/p/Category%7EAspirin_714d.html" title="Category:Aspirin">Aspirin</a></span></div></div></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../../articles/m/e/c/Mechanism_of_action_of_aspirin.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../../articles/m/e/c/Talk%7EMechanism_of_action_of_aspirin_892b.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Mechanism_of_action_of_aspirin">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../../misc/Wiki.png);"
	    href="../../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-mainpage"><a href="../../../../index.html">Main Page</a></li>
	     	      <li id="n-Contents"><a href="../../../../articles/c/o/n/Portal%7EContents_b878.html">Contents</a></li>
	     	      <li id="n-featuredcontent"><a href="../../../../articles/f/e/a/Portal%7EFeatured_content_5442.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../../articles/c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>Interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-aboutsite"><a href="../../../../articles/a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../../articles/c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-recentchanges"><a href="../../../../articles/r/e/c/Special%7ERecentChanges_e0d0.html">Recent changes</a></li>
	     	      <li id="n-contact"><a href="../../../../articles/c/o/n/Wikipedia%7EContact_us_afd6.html">Contact Wikipedia</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Donate">Donate to Wikipedia</a></li>
	     	      <li id="n-help"><a href="../../../../articles/c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../../misc/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 20:21, 10 June 2008 by Wikipedia user <a href="../../../../articles/c/r/a/User%7ECrazyChemGuy_85d0.html" title="User:CrazyChemGuy">CrazyChemGuy</a>. Based on work by Wikipedia user(s) <a href="../../../../articles/d/u/m/User%7EDumZiBoT_2099.html" title="User:DumZiBoT">DumZiBoT</a>, <a href="../../../../articles/a/l/a/User%7EAlaibot_de3d.html" title="User:Alaibot">Alaibot</a>, <a href="../../../../articles/w/a/s/User%7EWaster_f10d.html" title="User:Waster">Waster</a> and <a href="../../../../articles/i/o/m/User%7EIomesus_c4d4.html" title="User:Iomesus">Iomesus</a>.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Copyrights" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a U.S. registered <a class='internal' href="http://en.wikipedia.org/wiki/501%28c%29#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="http://en.wikipedia.org/wiki/Non-profit_organization" title="Non-profit organization">nonprofit</a> <a href="http://en.wikipedia.org/wiki/Charitable_organization" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../../articles/a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../../articles/g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
